The stronger outlook follows mixed results from other major medical device makers in the latest quarter, after both Abbott ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

Anteris Technologies is developing DurAVR, a differentiated biomimetic TAVR device with encouraging early clinical data in ...

A federal judge has paused the merger of the only two companies developing a heart device made for high-risk patients suffering from aortic regurgitation, a potentially dangerous condition that occurs ...

WASHINGTON — A phase 3 randomized trial will soon begin for the first transcatheter aortic valve replacement (TAVR) device for the treatment of aortic valve regurgitation after promising results in a ...

In the first head-to-head comparison of two devices intended to protect against stroke in patients undergoing transcatheter aortic valve replacement (TAVR), the investigational Emboliner device ...

Edwards Lifesciences Corp (EW) reports a robust 12.7% sales growth in Q1 2026, raises full-year guidance, and showcases significant advancements in TAVR and TMTT segments.

The FDA has granted pre-market approval to JenaValve’s Trilogy system, the first transcatheter aortic valve replacement (TAVR) device in the U.S. specifically indicated for severe aortic regurgitation ...

PHOENIX — Abrazo Arizona Heart Hospital in Phoenix became the first health center in the state to use a new device that serves as an alternative to open-heart surgery this week. Cardiologist Timothy ...

Indian-made Myval and Myval Octacor were put to the test against Sapien 3 in the noninferiority trial COMPARE TAVI-1. Noninferiority was demonstrated when counting deaths, strokes, moderate or severe ...

On August 6, the Federal Trade Commission (FTC) challenged Edwards Lifesciences Corp.'s proposed $945 million acquisition of JenaValve Technology, Inc. The deal would combine the two leading companies ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...